Request Demo

Last update 07 Jul 2026

Apatinib Mesylate

Last update 07 Jul 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Apatinib, Rivoceranib, Rivoceranib mesilate

+ [5]

Target

VEGFR2

Action

antagonists

Mechanism

VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersSkin and Musculoskeletal Diseases+ [5]

Active Indication

Germline BRCA-mutated, HER2-negative metastatic breast cancerHepatocellular CarcinomaGastroesophageal junction adenocarcinoma+ [42]

Inactive Indication

Adenoid Cystic CarcinomaAdvanced biliary tract cancerAdvanced cancer+ [49]

Originator Organization

Advenchen Laboratories LLC

Active Organization

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

HRYZ (Shanghai) Biotech Co., Ltd.

Inactive Organization

Elevar Therapeutics, Inc.

Bukwang Pharmaceutical Co., Ltd.

Shanghai Shengdi Pharmaceutical Co., Ltd.

License Organization

QureBio Ltd.

Bukwang Pharmaceutical Co., Ltd.

Elevar Therapeutics, Inc.

+ [6]

Drug Highest PhaseApproved

First Approval Date

China (17 Oct 2014),

Gastroesophageal junction adenocarcinomastomach adenocarcinoma

RegulationOrphan Drug (United States), Orphan Drug (European Union), Special Review Project (China), Orphan Drug (South Korea), National Science and Technology Major Project (China), Breakthrough Therapy (China), Priority Review (China)

Structure/Sequence

Molecular FormulaC25H27N5O4S

InChIKeyFYJROXRIVQPKRY-UHFFFAOYSA-N

CAS Registry1218779-75-9

1,094

Clinical Trials associated with Apatinib Mesylate

NCT07314203

/ Not yet recruitingPhase 3IIT

Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Exploring the pathological complete response rate (pCR) of locally advanced gastric cancer treated with adebelimab combined or not combined with apatinib mesylate and SOX neoadjuvant therapy

Start Date25 Dec 2026

Sponsor / Collaborator

Fujian Medical University

NCT07682272

/ Not yet recruitingPhase 2

A Randomized, Open-label, Multicenter Phase II Study of SHR-8068 Combined With Adebrelimab and Apatinib for Perioperative Treatment in Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk

This study is conducted to evaluate the efficacy and safety of SHR-8068 combined with Adebrelimab and Apatinib compared with Adebrelimab combined with Apatinib in perioperative treatment of resectable hepatocellular carcinoma with intermediate or high recurrence risk.

Start Date01 Jul 2026

Sponsor / Collaborator

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

NCT07653451

/ Not yet recruitingPhase 2/3IIT

Precision Medicine Strategies for Advanced Esophageal Cancer Refractory to Immune Checkpoint Inhibitors

This study is an open-label, biomarker-integrated umbrella trial designed to evaluate the clinical efficacy of molecular subtype- and genomic biomarker-guided precision therapies in patients with advanced esophageal cancer refractory to prior immunotherapy. Conducted in a two-step process, the study first enrolls patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed on prior immunotherapy, performing circulating tumor DNA (ctDNA) sequencing to stratify them into three distinct treatment cohorts, after which patients receive tailored combination regimens matched to their specific molecular profiling in the second step. Specifically, Cohort 1 includes patients with high EGFR expression or activation of EGFR-related signaling pathways, who will receive Afatinib (40 mg, p.o., Q.D.) combined with Toripalimab (240 mg, i.v., Q21D) in a 21-day treatment cycle, continuing until radiographic disease progression (PD), unacceptable toxicity, loss to follow-up, death, or other investigator-determined criteria for discontinuation, with a maximum toripalimab treatment duration of 24 months. Cohort 2 comprises patients harboring genomic alterations directly associated with cell cycle regulation or activation of cell cycle signaling pathways, who will be treated with Dalpiciclib (125 mg, p.o., Q.D. for 21 consecutive days followed by a 7-day off period in a 28-day cycle [Q4W]) combined with Pyrotinib maleate (320 mg, p.o., Q.D., administered within 30 minutes post-meal, Q4W) until disease progression, unacceptable toxicity, initiation of a new anti-tumor therapy, withdrawal of consent, or investigator's decision for treatment discontinuation. Cohort 3 includes patients with other molecular profiles who do not fit Cohorts 1 or 2, who will receive Camrelizumab (200 mg, i.v., Q3W) and Apatinib (250 mg, p.o., Q.D.), with clinical efficacy evaluations performed every 6 weeks, continuing until radiographic PD, unacceptable toxicity, death, or treatment discontinuation, whichever occurs first. The study aims to recruit an estimated maximum of 90 subjects, enrolling up to 30 subjects per cohort, with the final sample size dependent on the observed toxicities and the prevalence of each molecular cohort within the screened population.

Start Date01 Jul 2026

Sponsor / Collaborator-

100 Clinical Results associated with Apatinib Mesylate

100 Translational Medicine associated with Apatinib Mesylate

100 Patents (Medical) associated with Apatinib Mesylate

2,464

Literatures (Medical) associated with Apatinib Mesylate

01 Dec 2026·CURRENT TREATMENT OPTIONS IN ONCOLOGY

Systemic Therapy for Solitary Fibrous Tumor

Review

Author: Stergiopoulos, Georgios M ; Tinoco, Gabriel ; Robinson, Steven I

OPINION STATEMENT:

Solitary fibrous tumor (SFT) is an exceedingly rare mesenchymal neoplasm classified as a soft tissue sarcoma (STS). While historically considered indolent, up to 50% of cases can recur or metastasize after long-term follow-up. Complete surgical resection constitutes the cornerstone of treatment for localized disease, while the management of locally advanced or metastatic SFT poses a significant clinical challenge underscoring the need for effective systemic therapies. Antiangiogenic agents have shown promising outcomes, particularly in non-dedifferentiated SFT, and are increasingly favored by some as first-line options. Regarding chemotherapy, traditional anthracycline-based STS regimens have demonstrated limited efficacy, shifting the current focus towards combinations with alkylating agents, such as dacarbazine, and other agents such as microtubule inhibitors, like trabectedin. This review summarizes current systemic therapeutic strategies for SFT, highlighting the central role of antiangiogenic therapy as the standard backbone for managing advanced disease. It also discusses current data on chemotherapy, as well as molecularly targeted and immunomodulatory approaches, which are emerging options that require further validation. In addition, we discuss evolving concepts in systemic treatment sequencing, predictive biomarkers, advanced therapeutic combinations under clinical evaluation, and potential future therapeutic agents and targets.

01 Dec 2026·JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Synergistic Anticancer Effects of Apatinib and PD-L1 Inhibition in Breast Cancer

Article

Author: Xu, Juanjuan ; Guo, Cairu ; Han, Danyang

Abstract:

Studies in breast cancer have demonstrated that apatinib exhibits both antiangiogenic and antitumor effects, while PD-L1 inhibitors have similarly shown meaningful clinical benefit. Building upon these observations, this study evaluated the potential synergistic antitumor effects of combining apatinib with a PD-L1 inhibitor and examined the mechanistic basis for their interaction in breast cancer. Notably, we found that this regimen could significantly suppress the proliferation, migration, and invasion of MCF-7 and MDA-MB-231 cells, and promote cell apoptosis. In addition, the levels of p-ERK, NF-κB, and Slug were markedly reduced in vitro. Collectively, these findings support the potential clinical utility of combining apatinib and PD-L1 inhibition, as evidenced by consistent in vitro and in vivo synergy.

01 Sep 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Characterization of forced degradation products of tyrosine kinase inhibitor apatinib mesylate by LC-MS/MS and NMR with in silico toxicity assessment

Article

Author: Shevatkar, Jayesh ; Shaikh, Nadeem ; Khemchandani, Rahul ; Samanthula, Gananadhamu

Apatinib (APA) a potent tyrosine kinase inhibitor used to treat gastric carcinoma. The study presents the systematic forced degradation behaviour of APA and characterization of the formed degradation products (DPs) by LC-MS/MS and NMR. The stability of APA was evaluated under hydrolytic (acid, base, and neutral), oxidative, photolytic (UV and Visible), and solid thermal conditions. The resulting DPs were separated chromatographically by Waters XBridge C18 (250 × 4.6 mm, 5μm) column utilizing the mobile phase of 0.1% trifluoroacetic acid as solvent A and acetonitrile as solvent B. The potential DPs were characterized by interpreting the fragmentation pathway of APA based on LC-MS/MS results. The enriched DP, namely A-6, was isolated by HPLC and further characterized by 1D and 2D NMR data. A mechanistic pathway for the formation of DPs of APA was proposed. In line with ICH Q2 (R2), the developed HPLC assay method of APA was validated and established as linear, precise, specific, accurate, and robust in nature. In silico toxicity profile for APA and its DPs was evaluated by ADMET Predictor®, revealing the positive alerts across multiple toxicity endpoints. The present research provides the framework for drug development based on the stability behaviour of APA, and the developed HPLC method was utilized for routine stability and quality control analysis.

108

News (Medical) associated with Apatinib Mesylate

01 Jun 2026

·www.prnewswire.com

Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

SHANGHAI, June 1, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world's leading oncology conferences, the ASCO Annual Meeting serves as a key venue for presenting advances in cancer research and clinical development. This year, Hengrui Pharma presented more than 90 studies spanning multiple tumor types and therapeutic modalities. According to statistics, 94 Chinese research projects were selected for oral presentations at ASCO this year, including 12 late-breaking abstracts, marking the third consecutive year of growth. At 2026 ASCO Annual Meeting, Hengrui Pharma presented 91 accepted studies and 11 oral presentations featuring innovative therapies, underscoring the breadth of the company's oncology pipeline and ongoing investment in innovative drug development. As a leading innovative pharmaceutical company in China, Hengrui continues to focus on oncology research and drug development. For 16 consecutive years, Hengrui has shared data from its oncology portfolio at the ASCO Annual Meeting. This year, the company's research program encompasses multiple key areas, including gastrointestinal cancers, breast cancer, lung cancer, urological cancers, gynecological cancers, and supportive cancer care, covering 11 approved medicines, 10 pipeline candidates, and one Class 2 new drug (NMPA classification). These programs are supported by more than 10 technology platforms covering small molecules, ADCs, bispecific and multispecific antibodies, and degraders. Together, these platform-based R&D capabilities support a broad oncology pipeline encompassing multiple therapeutic approaches across different tumor types. Breast Cancer: New Data Support Multiple Emerging Treatment Strategies For triple-negative breast cancer, the HELEN-Trio 011 study led by Professor Zhenzhen Liu of Henan Cancer Hospital showed that the pathological complete response (pCR) rate for neoadjuvant therapy with camrelizumab combined with chemotherapy reached 57.5%, significantly outperforming the pCR of 45.4% observed with chemotherapy alone. In the field of neoadjuvant therapy for HER2-positive early breast cancer, the HELEN HER-013 study was the first to demonstrate that the chemotherapy-de-escalated regimen of nanoparticle albumin-bound paclitaxel, trastuzumab, and the tyrosine kinase inhibitor pyrotinib (nab-PHPy) is noninferior to standard TCHP, offering a new treatment option for patients who cannot tolerate severe hematologic toxicity. Gastrointestinal Cancers: ADC and Immunotherapy Combination Treatments Show Promise In the field of colorectal cancer, the HORIZON-CRC01 study led by Professor Jin Li of Shanghai GoBroad Cancer Hospital Affiliated to China Pharmaceutical University and Professor Ying Yuan of The Second Affiliated Hospital of Zhejiang University School of Medicine demonstrated that the new-generation anti-HER2 ADC, trastuzumab rezetecan, when used to treat patients with HER2-positive, RAS and RAF wild-type advanced colorectal cancer who have progressed after standard second-line therapy, achieved a median progression-free survival (PFS) of 5.5 months, compared to 2.8 months with conventional chemotherapy, suggesting a potential new treatment option for patients whose disease has progressed following standard therapies. In the field of liver cancer, the CARES-336 study, co-led by Academician Jia Fan from Zhongshan Hospital Affiliated to Fudan University and Professor Shukui Qin from Tsientang Institute for Advanced Study, has for the first time demonstrated that the "Camrelizumab + Apatinib" regimen combined with transarterial chemoembolization (TACE) significantly prolongs median PFS compared to TACE alone (by BIRC per mRECIST, 11.1 months vs. 8.3 months), supporting the potential use of this combination approach in patients with unresectable hepatocellular carcinoma (uHCC). Urological Cancers: Dual Breakthroughs in Prostate and Bladder Cancers The FUZUPRO study, led by Professor Dingwei Ye of Fudan University Shanghai Cancer Center, demonstrated that first-line treatment with fluzoparib combined with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer (mCRPC) resulted in a median radiographic PFS of 24.8 months, compared to 19.9 months with the standard regimen. Another study demonstrated that the anti-Nectin-4 ADC SHR-A2102 combined with adebrelimab achieved a pCR of 48.1% and a pathological downstaging rate of 59.3% in the perioperative treatment of muscle-invasive bladder cancer, including those with renal dysfunction. Supportive Cancer Care: Additional Evidence for New Antiemetic Drug The Phase III PROTECT study, led by Professor Li Zhang and Professor Yuhong Li of the Sun Yat-sen University Cancer Center, demonstrated that Fosrolapitant and Palonosetron Hydrochloride for Injection—a novel, ultra-long-acting antiemetic developed in-house by Hengrui—achieved significantly higher complete response rates than the standard regimen during the acute, delayed, and overall phases for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. These findings add to the growing body of clinical evidence supporting its use in supportive cancer care. Hengrui Pharma currently markets 16 approved oncology medicines in China and is advancing nearly 60 oncology candidates across its research portfolio. The company is conducting more than 150 clinical trials worldwide across its key oncology development programs. Hengrui's expanding presence at the ASCO Annual Meeting reflects continued progress across its oncology pipeline and broader clinical development efforts. The company's research presentations this year span multiple tumor types and therapeutic modalities, highlighting both approved medicines and investigational candidates across its oncology portfolio. As oncology research continues to evolve globally, Hengrui remains focused on translating scientific innovation into potential clinical benefit for patients through sustained investment in research and development. SOURCE Hengrui Pharma 21% more press release views with Request a Demo

ASCOPhase 3Clinical Result

31 Mar 2026

·allsci.com

Lancet: Chia Tai’s benmelstobart and anlotinib combo outperforms pembrolizumab in lung cancer trial

Researchers across 79 centers in China reported that a combination regimen of programmed death-ligand 1 (PD-L1) inhibitor benmelstobart plus the multi-kinase inhibitor anlotinib produced statistically significant improvements in progression-free survival over pembrolizumab monotherapy in PD-L1-positive, driver gene-negative advanced non-small-cell lung cancer (NSCLC), according to the CAMPASS Phase III trial. The results were published in The Lancet Oncology. The trial, funded by Chia Tai Tianqing Pharmaceutical Group, enrolled 531 patients and represents one of the first randomized Phase III datasets to demonstrate head-to-head superiority over pembrolizumab in this setting. Chia Tai is responsible for discovering benmelstobart and development in Greater China, while US-based biotech Apollomics partnered with the China-based firm for rights outside China. Pembrolizumab monotherapy has held a dominant position as first-line treatment for PD-L1-positive advanced NSCLC since its approval based on the KEYNOTE-024 and KEYNOTE-042 trials. However, a substantial proportion of patients progress within a year, and response rates in the broader PD-L1-positive population—defined as tumor proportion score (TPS) of 1% or greater—remain around 30% to 40%. The CAMPASS trial was designed to test whether adding anlotinib, a multi-target anti-angiogenic tyrosine kinase inhibitor, to the PD-L1-targeted benmelstobart could improve outcomes without the addition of chemotherapy. The CAMPASS results The trial randomized patients 2:1, with 354 receiving benmelstobart plus anlotinib and 177 receiving pembrolizumab plus placebo. Patients were aged 18 to 75 years, had an ECOG performance status of 0 or 1, and had no targetable EGFR or ALK mutations. Both squamous and non-squamous histologies were included. Enrollment ran from August 2021 through December 2022 across 79 sites in China. The primary endpoint was progression-free survival assessed by blinded independent central review per RECIST v1.1. Median PFS in the experimental arm was not reached at the time of analysis, compared with 8.9 months in the pembrolizumab arm. The hazard ratio was 0.51 (95% CI: 0.39–0.67; p<0.0001). The 12-month PFS rate was approximately 60% with benmelstobart plus anlotinib versus approximately 40% with pembrolizumab. The PFS benefit was consistent across prespecified subgroups, including patients with TPS 1%–49% and ≥50%, as well as across squamous and non-squamous histologies. Overall survival data, while still maturing with both medians not yet reached, showed a hazard ratio of 0.62 (95% CI: 0.44–0.88; p0.007), indicating an early OS signal in favor of the combination. The objective response rate was approximately 63% in the experimental arm versus 39% in the pembrolizumab arm, a statistically significant difference. The mechanistic rationale for the combination centers on the relationship between tumor angiogenesis and immune suppression. Tumors upregulate VEGF signaling to promote vascular growth, but this process also creates an immunosuppressive microenvironment by reducing T-cell infiltration and promoting regulatory T-cell accumulation. Anlotinib inhibits VEGFR, FGFR, PDGFR, and c-Kit, which normalizes tumor vasculature and is thought to improve T-cell trafficking into the tumor. Benmelstobart then blocks the PD-1/PD-L1 axis, reactivating cytotoxic T-cells within a more accessible microenvironment. The hypothesis is that anti-angiogenic therapy potentiates checkpoint inhibition by making tumors more immunologically permissive, rather than relying on checkpoint blockade alone. The safety profile reflected the dual-agent mechanism. Grade 3 or higher treatment-related adverse events occurred in approximately 60% of patients in the benmelstobart plus anlotinib arm, compared with approximately 35% in the pembrolizumab arm. Anlotinib-related toxicities, particularly hypertension and proteinuria, accounted for a meaningful share of the higher adverse event burden. Treatment discontinuation rates were higher in the experimental arm, however, no new or unexpected safety signals were identified. The investigators characterized the toxicity as manageable with dose modifications. Research context The CAMPASS regimen represents one among several competing approaches to the same problem. Akeso’s ivonescimab, a bispecific antibody targeting both PD-1 and VEGF within a single molecule, reported superiority over pembrolizumab in the HARMONi-2 Phase III trial in 2024 in a Chinese PD-L1-positive NSCLC population. Summit Therapeutics holds ex-China rights to ivonescimab, and the asset has attracted considerable attention as a potential pembrolizumab alternative in the first-line setting. The bispecific format is mechanistically adjacent to the CAMPASS combination but consolidates both activities into one molecule, which may carry pharmacokinetic and dosing advantages. Other China-developed IO combinations—including camrelizumab plus apatinib from Jiangsu Hengrui and sintilimab plus anlotinib from Innovent—are also in late-stage evaluation in overlapping populations. Roche’s atezolizumab plus bevacizumab plus chemotherapy (IMpower150) is approved in non-squamous NSCLC but includes cytotoxic chemotherapy, a distinction that the CAMPASS regimen avoids. The chemotherapy-free design is a feature it shares with the ivonescimab approach, with both positioning against pembrolizumab monotherapy in PD-L1-positive advanced NSCLC. The CAMPASS dataset was generated entirely in China, which carries implications for regulatory and commercial strategy. The trial population reflects a Chinese clinical context, and generalizability to Western populations will require additional data or bridging studies before regulatory submissions outside China. The benmelstobart program is also being evaluated in extensive-stage small-cell lung cancer, where a Phase III trial published in Nature Medicine in 2024 suggests Chia Tai Tianqing is pursuing a broader oncology footprint for the combination platform. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 3Clinical ResultDrug Approval

29 Jan 2026

·elevartx.com

Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy

Former CEO Dr. Bryan Kim will retain current role as CEO of Verismo Therapeutics Fort Lee, N.J., Jan. 29 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Group and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that Dong-Gun (DG) Kim has been appointed its Chief Executive Officer. He will concurrently retain his roles as CEO of HLB US and CEO of Immunomic Therapeutics, Inc., both affiliated companies within HLB Group. At Elevar, DG Kim replaces Dr. Bryan Kim, who will remain CEO of HLB Group’s Verismo Therapeutics, Inc. With Elevar having this week submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration for its top two developmental drugs, the transition allows Bryan Kim to now solely focus on his role with Verismo, which expects to reach several important milestones in the coming year. On January 23, 2026, Elevar submitted an NDA for the combination of its drug candidate rivoceranib, a VEGFR-TKI, and Hengrui Pharma’s camrelizumab, an anti-PD-1 antibody, as a first-line therapy for unresectable hepatocellular carcinoma (uHCC). HCC is the most common type of liver cancer. Elevar also submitted an NDA on January 27, 2026, for its investigational drug lirafugratinib as a second-line treatment option for cholangiocarcinoma (CCA) with fibroblast growth factor receptor (FGFR2) fusions or rearrangements. CCA is also known as bile duct cancer. “Bryan Kim has done an exemplary job steering Elevar through the regulatory and developmental steps leading to NDAs for both the rivoceranib-camrelizumab combination in the liver cancer arena and lirafugratinib as a bile duct cancer therapy,” said DG Kim, an Elevar board member since 2020. “With this critical phase completed, I look forward to executing on our commercialization strategy while simultaneously working to meet any requests from the FDA during its review of these important applications.” DG Kim previously served as CEO of HLB Co. Ltd. Prior to that, he spent more than 30 years as a specialist in mergers & acquisitions, corporate finance and investment management at leading corporations and professional firms (law, investment banking and private equity) both in the U.S. and Korea. He holds an A.B. in Physics from Harvard College and a J.D. from Harvard Law School. For more information about Elevar, visit ElevarTX.com About Elevar Therapeutics Elevar Therapeutics, Inc. is a fully integrated biopharmaceutical company built on the promise of elevating treatment outcomes for patients who have limited or inadequate therapeutic options. A subsidiary of HLB Group based in Fort Lee, New Jersey, Elevar’s expertise is rooted in oncology and grounded in compassion. Our team of experienced scientists and industry leaders is highly focused on identifying and developing medicines for complex yet under-treated health conditions, with a shared goal of making a meaningful difference in the lives of patients. For more information, follow us on LinkedIn and Twitter or visit ElevarTX.com. Media Contact: Rosemary Ostmann RoseComm rostmann@rosecomm.com (201) 615-7751

Executive ChangeNDA

100 Deals associated with Apatinib Mesylate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Apatinib Mesylate	L01XE	DB14765

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Germline BRCA-mutated, HER2-negative metastatic breast cancer	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Dec 2024
Hepatocellular Carcinoma	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	07 Jan 2021
Gastroesophageal junction adenocarcinoma	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	17 Oct 2014
stomach adenocarcinoma	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	17 Oct 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic hepatocellular carcinoma	NDA/BLA	United States	Elevar Therapeutics, Inc.	21 Oct 2024
Unresectable Hepatocellular Carcinoma	NDA/BLA	United States	Elevar Therapeutics, Inc.	17 May 2023
Stomach Cancer	NDA/BLA	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	09 Aug 2011
Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	21 Sep 2020
Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Sep 2020
Advanced Triple-Negative Breast Carcinoma	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Jul 2020
Breast Cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	03 Jul 2020
Metastatic breast cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	03 Jul 2020
PD-L1 positive Lung Cancer	Phase 3	-	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	15 Jun 2020
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	-	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	15 Jun 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2026	Not Applicable	Hepatocellular Carcinoma VEGFR-2	10	TACE + apatinib	ecxyqrhfxe(dxmemmwxgq) = ubwlkyzfhy ieifdehtkg (zuyeiknuzx, 0.75 - 0.82) View more	Positive	29 May 2026
ASCO2026	Phase 2	Intrahepatic Cholangiocarcinoma	17	Tislelizumab+ Apatinib +HAIC	bxsncjjdvh(aiwlcnwhwj) = pgjrlzalmx utyzezcukd (gmrxdacmbg, 18.4 - 67.1) View more	Positive	29 May 2026
NCT05320692 (ASCO2026)	Phase 3	Unresectable Hepatocellular Carcinoma First line	423	Camrelizumab (C) + Rivoceranib (R) + TACE	rhedrexrnl(wkkhnamdiv) = tllafzgkyc gpnnsxmybt (jjurlmoewn, 7.8 - 14.0) View more	Positive	29 May 2026
				TACE	rhedrexrnl(wkkhnamdiv) = okkpjbamfc gpnnsxmybt (jjurlmoewn, 6.9 - 9.5) View more
ChiCTR2300069990 (ASCO2026)	Phase 2	Neoadjuvant	9	Apatinib plus Camrelizumab	wckqxfhdfi(jwvbmllbgh) = xxntkxfsdm xgnrgruxzy (spyfjefecl ) View more	Positive	29 May 2026
NCT07314372 (FAD-HCC-01, ASCO2026)	Phase 2	Unresectable Hepatocellular Carcinoma FAD subtypes (F1, F2, or F3)	86	camrelizumab+rivoceranib (F1 or F2 subtype)	sgrmdjdrot(dczmeudckk) = The most common treatment-related adverse events were Grade 2-3 hypertension (camrelizumab, 53.8%; TACE, 39.7%) and Grade 1-2 diarrhea (rivoceranib, 47.6%). flzbssjrrk (szajuqpsxz )	Positive	29 May 2026
				camrelizumab+rivoceranib+TACE (F3 subtype)
NCT06925516 (ACADEMY, ASCO2026)	Phase 2	Intrahepatic Cholangiocarcinoma First line	22	Apatinib + adebrelimab + GEMOX	pfyqzfkcrl(wfdqouwpos) = lcvdinuypp rxxcqfxlcc (ppnbepezks ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Osteosarcoma	37	Low-dose apatinib + HD-MTX + DOX + DDP + IFO	zrevhipnmv(rbeevexlcp) = guezohidjw vvpzbxyybi (xftgpwclvp ) View more	Positive	29 May 2026
NCT05512481 (CAP 03-NEO, ASCO2026)	Phase 2	Acral Lentiginous Malignant Melanoma Neoadjuvant	60	Neoadjuvant camrelizumab + apatinib + temozolomide	onpzdqipxu(ahqletrsay) = busendouke ixilbpqeak (vpdmwdqmba ) View more	Positive	29 May 2026
				Adjuvant PD-1 inhibitor	-
NCT04588987 (ASCO2026)	Phase 2	High grade glioma Neoadjuvant	28	Camrelizumab 200mg + Apatinib 250mg	ejwijxjjuq(bgrrklocwt) = eorbbqgopv uybllyicyw (ccvxowhiwk, 8.82 - 13.38) View more	Positive	29 May 2026
				Camrelizumab 200mg + Apatinib 250mg (glioblastoma)	ejwijxjjuq(bgrrklocwt) = rplbjfihwz uybllyicyw (ccvxowhiwk, 8.3 - 15.04) View more
NCT05759572 (ASCO2026)	Phase 1/2	Hormone receptor positive HER2 negative breast cancer First line HR+ \| HER2-	145	Apatinib+dalpiciclib with ET	bxqveuvwio(epzmvyiuxc) = emkqhtcdkz famuiruzeu (vmfxmbgrkt ) View more	Positive	29 May 2026
				Dalpiciclib with ET	bxqveuvwio(epzmvyiuxc) = eicrfhdzvu famuiruzeu (vmfxmbgrkt ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Apatinib Mesylate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation